Type de procédure : Information absente Type de document : Avis de préinformation ou avis périodique indicatif utilisé uniquement à titre d’information
Grande-Bretagne
Royaume-Uni, Espagne, Danemark, Pologne, Grèce - Services de recherche et développement expérimental - PreCommercial Procurement (PCP) to buy R&D (research and development) services on innovative and sustainable solutions to transition healthcare supply chains from linear to circular models - REHEAL.
Royaume-Uni, Espagne, Danemark, Pologne, Grèce – Services de recherche et développement expérimental – PreCommercial Procurement (PCP) to buy R&D (research and development) services on innovative and sustainable solutions to transition healthcare supply chains from linear to circular models – REHEAL.
OJ S 246/2025 22/12/2025
Avis de préinformation ou avis périodique indicatif utilisé uniquement à titre d’information
Services
1.Acheteur
1.1.
Acheteur
Nom officiel: NHS National Services Scotland (NSS)
Forme juridique de l’acheteur: Organisme de droit public
Activité du pouvoir adjudicateur: Santé
2.Procédure
2.1.
Procédure
Titre: PreCommercial Procurement (PCP) to buy R&D (research and development) services on innovative and sustainable solutions to transition healthcare supply chains from linear to circular models – REHEAL.
Description: This PIN provides early information about the expected starting date and purchase volume and about the open market consultation that is organised in preparation of this precommercial procurement (PCP). The procurement aims to trigger new solutions to be developed and tested to address the following challenge: REHEAL aims to stimulate the development of new solutions that will support the transition of healthcare supply chains from linear to circular models to enhance sustainability and resilience. Key areas include developing supply chain management platforms that prioritise product longevity, material tracking, and regulatory compliance, employing advanced data analytics and AI to optimise reverse logistics and explore recovery opportunities. Solutions should enable scenario analysis and modelling, allowing healthcare providers to identify and implement the most impactful strategies tailored to regional needs.
2.1.1.
Objet
Nature du marché: Services
Nomenclature principale(cpv): 73100000Services de recherche et développement expérimental
Nomenclature supplémentaire(cpv): 73110000Services de recherche, 72212445Services de développement de logiciels de gestion des relations clientèle (CRM), 72222300Services de technologies de l'information, 90713000Services de conseils environnementaux, 90714100Systèmes d'information environnementale, 90711300Analyse des indicateurs environnementaux autres que pour la construction, 80500000Services de formation, 79342200Services de promotion, 90711000Évaluation de l'impact sur l'environnement autre que pour la construction, 72212783Services de développement de logiciels de gestion de contenu, 85100000Services de santé
2.1.2.
Lieu d’exécution
Ville: Edinburgh
Code postal: EH12 9EB
Pays: Royaume-Uni
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
2.1.2.
Lieu d’exécution
Ville: Lugo
Subdivision pays (NUTS): Lugo(ES112)
Pays: Espagne
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
2.1.2.
Lieu d’exécution
Ville: Copenhagen
Subdivision pays (NUTS): Københavns omegn(DK012)
Pays: Danemark
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
2.1.2.
Lieu d’exécution
Ville: Kraków
Subdivision pays (NUTS): Miasto Kraków(PL213)
Pays: Pologne
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
2.1.2.
Lieu d’exécution
Ville: Attiki
Subdivision pays (NUTS): ??t??? ?tt???(EL306)
Pays: Grèce
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
2.1.3.
Valeur
Valeur estimée hors TVA: 3 000 000,00EUR
2.1.4.
Informations générales
Informations complémentaires: The research and development (R&D) services will be carried out primarily within the European Union and/or in countries associated with the Horizon Europe Programme. At least 50% of the total value of the R&D activities shall take place within the EU or associated countries. Contractors must ensure that none of the contracted services are performed in countries nor by entities that are subject to EU restrictive measures under Article 29 of the Treaty on the European Union (TEU) and Article 215 of the Treaty on the Functioning of the EU (TFEU)23 (sanctions). They must also ensure that none of the goods procured or used for the procurement were developed, produced or supplied in countries or by entities that are subject to such restrictive measures. This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs. Publication of this contract notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation. This PIN is published to announce an open market consultation on a future procurement procedure. The PIN is not a commitment to procure. This procurement is funded by the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement No. 101226919 – ReHEAL https://www.rehealhorizon.eu . *The EU has awarded a grant for this procurement but is not participating as a contracting authority in the procurement.* For additional information, please contact: REHEAL Project Coordination Team, Email:pcp@rehealhorizon.eu More information is on the REHEAL website https://www.rehealhorizon.eu.
Base juridique:
Autre
3.Partie
3.1.
Identifiant technique de la pièce: PAR-0001
Titre: PreCommercial Procurement (PCP) to buy R&D (research and development) services on innovative and sustainable solutions to transition healthcare supply chains from linear to circular models – REHEAL.
Description: This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (socalled ‘Buyers Group’).The procurement will take the form of a precommercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions. Each selected R&D provider will be awarded a framework agreement that covers the following R&D phases and a specific contract per phase.Procurement will take the form of a precommercial procurement (PCP), that will allow procurers to buy R&D from several competing suppliers in parallel; to compare alternative solution approaches and to identify the best valueformoney solutions that the market can deliver to address those needs. The PCP will be structured as a fasttrack PCP, specifically designed to accelerate innovation cycles and reduce timetoimpact whilst remaining fully compliant with Horizon Europe PCP principles. In contrast to traditional PCPs that strictly separate prototyping and piloting into distinct phases, REHEAL adopts a fasttrack approach in which prototyping and piloting are combined into a single integrated R&D phase. This approach is justified by the digital, softwareintensive nature of the expected solutions, which enables rapid iteration, continuous testing and early validation in real operational environments. The PCP will be organised into three consecutive phases: Phase 1 – Solution design and feasibility: Selected contractors will elaborate detailed solution designs, technical architectures, and feasibility studies addressing the REHEAL challenge, including risk assessment and validation plans. Phase 2 – Prototyping and piloting (combined phase): Contractors will develop functional prototypes and pilot them directly in operational healthcare environments across the Buyers Group sites. Prototyping and piloting are grouped together to enable rapid learning loops, realworld testing, and early assessment of usability, scalability, sustainability impact, and integration into existing healthcare supply chains. Phase 3 – followup procurement: subject to the successful completion of Phase 2 and availability of funding, the REHEAL Buyers Group may launch a separate followup procurement to deploy and upscale the most promising solution(s). This Phase 3 is not part of the PCP itself, but is foreseen as a potential next step to ensure market uptake and impact, in line with Horizon Europe PCP guidance. After each PCP phase, interim evaluations will be carried out, and the contractors offering the best value for money will be invited to progress to the next phase. Each selected operator will receive a framework contract, with specific contracts awarded per phase. The selected operators will retain ownership of the intellectual property rights (IPRs) they generate during the PCP and will be able to use them to exploit the full market potential of the solutions developed. All interested operators are invited to take part in the upcoming open market consultation (OMC) (regardless of their geographic location, size or governance structure of their organisation). The OMC will be organised as a series of meetings. These meetings will provide you with an overview on the procurement objectives, the PCP process and the main clauses of the contract. You will also have the opportunity to ask questions. A first EUlevel online webinar will be held on 11 February 2026, introducing the project, challenge, requirements, Buyers Group, overall PCP process and timeline, to tools available to support applicants. This will be followed by a series of five live meetings hosted in each of the procurer locations mentioned in under Section I.1) During those meetings, the procurers will offer presentations in their own local languages, namely English, Spanish, Danish, Polish and Greek. These meetings will take place between 16 – 27 February 2026. The meetings will be followed by an EUlevel live event on 4 March and a final EU webinar, on 31 March 2026, in English. Registration for OMC meetings will be available on the REHEAL website https://www.rehealhorizon.eu – from 19 January 2026. The contract notice is expected to be published in July 2026 and the procurement is expected to start in late 2026 and end in late 2028. Testing is expected to take place in Scotland (UK), Galicia (Spain), Region Hovedstaden (Denmark), Krakow (Poland), and Athens (Greece). This testing may also serve as a first customer test reference for the contractors. The selected suppliers will retain ownership of the intellectual property rights (IPRs) they generate during the PCP and will be able to use them to exploit the full market potential of the solutions developed, i.e. beyond the procurement.
3.1.1.
Objet
Nature du marché: Services
Nomenclature principale(cpv): 73100000Services de recherche et développement expérimental
3.1.2.
Lieu d’exécution
Ville: Edinburgh
Pays: Royaume-Uni
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
3.1.2.
Lieu d’exécution
Ville: Lugo
Subdivision pays (NUTS): Lugo (ES112)
Pays: Espagne
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
3.1.2.
Lieu d’exécution
Ville: Copenhagen
Subdivision pays (NUTS): Københavns omegn (DK012)
Pays: Danemark
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
3.1.2.
Lieu d’exécution
Ville: Kraków
Subdivision pays (NUTS): Miasto Kraków (PL213)
Pays: Pologne
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
3.1.2.
Lieu d’exécution
Ville: Attiki
Subdivision pays (NUTS): ??t??? ?tt??? (EL306)
Pays: Grèce
Informations complémentaires: Testing is expected to take place in United Kingdom (Scotland), Spain (Galicia), Denmark (Region Hovedstaden); Poland (Malopolska Region), Greece (Attiki)
3.1.3.
Durée
Autre durée: Inconnu
3.1.4.
Valeur
Valeur estimée hors TVA: 3 000 000,00EUR
3.1.5.
Informations générales
Le marché relève de l’accord sur les marchés publics (AMP): non
Le marché en question convient aussi aux petites et moyennes entreprises (PME): oui
3.1.9.
Informations complémentaires, médiation et réexamen
Organisation chargée des procédures de médiation: NHS National Services Scotland (NSS)
Organisation chargée des procédures de recours: NHS National Services Scotland (NSS)
Organisation qui fournit des précisions concernant l’introduction des recours: NHS National Services Scotland (NSS)
8.Organisations
8.1.
ORG-0001
Nom officiel: NHS National Services Scotland (NSS)
